Exploring a genetic basis for the metabolic perturbations in ME/CFS using UK biobank.
Huang, Katherine, Muneeb, Muhammad, Thomas, Natalie et al. · iScience · 2026 · DOI
Quick Summary
Researchers examined blood samples from nearly 900 ME/CFS patients to understand how genes influence metabolism in this condition. They found that people with ME/CFS have different genetic patterns affecting fat and lipid metabolism compared to healthy people, particularly involving genes related to immune function. These genetic differences may help explain why ME/CFS affects different people in different ways.
Why It Matters
This study provides genetic evidence for distinct metabolic abnormalities in ME/CFS, potentially explaining why patients experience different symptoms and disease severity. Understanding the metabolic basis of ME/CFS may lead to biomarkers for patient stratification and inform development of targeted treatments. The identification of specific genetic pathways offers a scientific foundation for investigating mechanism-based therapeutic interventions.
Observed Findings
112 genetic variants showed significant associations with plasma biomarkers in ME/CFS patients, substantially fewer than the 4,114 observed in healthy controls.
Two genetic variants specific to ME/CFS mapped to HSD11B1 and SCGN genes, associated with abnormal lipid profiles in extra-large VLDL particles and total fatty acids.
Genetic effects on VLDL-related traits showed among the least correlation between ME/CFS and healthy control groups, indicating disease-specific genetic mechanisms.
Enrichment analysis identified three immune-regulatory genes (ADAP1, NR1H3, CD40) showing differential genetic effects for lipid traits between groups.
Pathway analysis highlighted enrichment in lipid metabolism, neurotransmitter transport, and inflammatory pathways specific to ME/CFS.
Inferred Conclusions
ME/CFS has a polygenic basis with many small-effect genetic variants jointly perturbing metabolic mechanisms, contributing to disease heterogeneity.
Immune-related genes that regulate lipid metabolism show differential genetic effects in ME/CFS, suggesting a link between immune dysregulation and metabolic abnormalities.
The distinct pattern of genetic-metabolic associations in ME/CFS compared to healthy controls supports the existence of disease-specific biological mechanisms.
Remaining Questions
Do the identified genetic variants directly cause metabolic dysfunction, or are they markers of other causal mechanisms in ME/CFS?
What This Study Does Not Prove
This study identifies genetic associations with metabolic biomarkers but does not prove these genetic variants cause ME/CFS or that correcting these metabolic abnormalities will improve symptoms. The findings are correlational and come from a cross-sectional analysis, so causality cannot be established. Additionally, genetic susceptibility does not mean genetic determinism—environmental and other factors are clearly also important in ME/CFS development.
How do identified metabolic perturbations relate to clinical symptoms and could they be used as biomarkers to predict treatment response or disease severity?
What environmental, epigenetic, or acquired factors interact with these genetic variants to trigger ME/CFS development and progression?
Can the polygenic metabolic signature be used to stratify ME/CFS patients into mechanistically distinct subtypes that might respond to different treatments?